It was suggested that there is a general correlation of mutation load within tumor DNA and efficacy of immune checkpoint inhibition, irrespective of targeting PD-1 or its ligand, likely by an increased expression of tumor associated neoantigens [195–197]. This evidence concerns the gene PDCD1 and neoplasm.